RECURSION PHARMACEUTICALS INC. - CLASS A COMMON S

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

16 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Recursion to Participate in Upcoming Investor Conference

02 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Recursion Publishes Annual Environmental, Social and Governance Report

26 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Recursion Announces Plans to Open New Office in London

11 Mar 2024 04:00:00 By Nasdaq GlobeNewswire

Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community

01 Mar 2024 14:58:00 By Nasdaq GlobeNewswire

Recursion to Participate in Upcoming Investor Conferences

01 Mar 2024 07:59:00 By Nasdaq GlobeNewswire

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results

27 Feb 2024 16:05:11 By Nasdaq GlobeNewswire

Recursion to Host Public L(earnings) Call on February 27

20 Feb 2024 07:59:00 By Nasdaq GlobeNewswire

Altitude Lab Startups Raise Over $120M in Capital

24 Jan 2024 09:00:00 By Nasdaq GlobeNewswire

Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference

08 Jan 2024 10:59:00 By Nasdaq GlobeNewswire

Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline

04 Jan 2024 07:59:00 By Nasdaq GlobeNewswire

Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8

03 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry

20 Dec 2023 07:59:00 By Nasdaq GlobeNewswire

Bayer and Recursion Focus Research Collaboration on Oncology

09 Nov 2023 09:41:30 By Nasdaq GlobeNewswire

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology

09 Nov 2023 08:01:00 By Nasdaq GlobeNewswire

Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results

09 Nov 2023 07:58:00 By Nasdaq GlobeNewswire

Recursion to Participate in Upcoming Investor Conference

02 Nov 2023 08:05:00 By Nasdaq GlobeNewswire

Recursion to Participate in Upcoming Investor Conferences

05 Sep 2023 16:30:00 By Nasdaq GlobeNewswire

Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection

05 Sep 2023 07:59:00 By Nasdaq GlobeNewswire

Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds

08 Aug 2023 08:00:01 By Nasdaq GlobeNewswire